Shorted
Imugene logo
IMU
Pharmaceuticals, Biotechnology & Life Sciences

Imugene

Short interest
0.31%
−0.03 pp 30d
as of 12 Oct 2026
Reported shorts
1.7M
Shares on issue
548.902M

Imugene (IMU) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
28 Sept

Which Catalysts Matter for Imugene (ASX:IMU) Near Yearly Lows?

Highlights Imugene shares are trading close to their yearly low despite a run of clinical updates on its lead cell therapy. Fresh capital and new institutional backers arrived over winter, alongside a change at the top. Upcoming trial data, regulatory progress and cash management will shape sentiment from here. Imugene (ASX:IMU) enters the final week of September trading close to its yearly low, as the clinical-stage immuno-oncology company tries to convert a string of encouraging updates on ...

Continue reading
Kalkine
Neutral
24 Sept

Are Imugene's Azer-Cel Responses Building Momentum (ASX:IMU)?

Highlights Imugene continues enrolling patients in the concurrent BTK inhibitor cohort of its azer-cel blood cancer trial. The company reported a first complete response in that cohort in July, after presenting early data at a major oncology meeting in June. As a clinical-stage company without product revenue, Imugene remains exposed to trial outcomes and funding needs. Imugene (ASX:IMU) remains on the radar today among Australian small-cap biotechs as it continues enrolling patients in the c...

Continue reading
Kalkine
Neutral
1 Sept

Imugene Directors Kim Drapkin, Jakob Dupont, and Lesley Russell Report Expiry of $4.012 Options on August 31, 2026

Imugene Limited (ASX:IMU) has announced that directors Kim Drapkin, Jakob Dupont, and Lesley Russell each had options expiring on 31 August 2026 lapse unexercised, as detailed in Change of Director's Interest Notices filed with the ASX under listing rule 3.19A.2. Key Points Directors Drapkin, Dupont, and Russell held options priced at $4.012 expiring on 31 August 2026, which expired without exercise or conversion. Kim Drapkin disposed of 3,502 options and currently holds zero options of that ...

Continue reading
Kalkine
Neutral
17 July

Imugene Limited Announces Expiry of 5,845 Restricted Stock Units Due to Unmet Conditions

Imugene Limited (IMU), an Australian biotechnology firm, has informed the ASX about the expiry of 5,845 restricted stock units following the failure to meet attached conditions. These units lapsed on 15 June 2026 after the stipulated requirements were not fulfilled or became impossible to satisfy. This event represents a minor modification within the company’s overall capital structure, which remains largely unchanged. Key Points Imugene Limited (IMU) is an Australian biotech company listed...

Continue reading
Kalkine
Neutral
22 May

Imugene Advances Cancer Research With Azer-cel Progress

Highlights Azer-cel trial shows encouraging patient responses Study focuses on difficult blood cancer cases Imugene expands immunotherapy research momentum Imugene continues advancing its immuno-oncology pipeline as fresh clinical findings from its azer-cel study highlight encouraging treatment activity in difficult blood cancer cases. Clinical-stage immuno-oncology company Imugene (ASX:IMU) has drawn market attention after releasing fresh clinical findings linked to its azer-cel therap...

Continue reading